Efficacy and safety of concomitant use of three immunosuppressant therapy for anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia
Phase 4
- Conditions
- dermatomyositis with interstitial pneumonia
- Registration Number
- JPRN-UMIN000014344
- Lead Sponsor
- Kyoto University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have active tuberculosis or hepatitis B virus infection. Patients who have malignancy when dermatomyositis is diagnosed. Patients under 16 years old.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Probability of survival at 6 month and safety.
- Secondary Outcome Measures
Name Time Method Change of symptom, biomarker (ferritin, IL-6, IL-18, M-CSF), titer of anti-MDA5 antibody, and chest CT.